Physician profile
Adil Imran
NPI 1750410999
$3,133.83
in general payments reported to CMS, 2019-2025
24 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $68.63 · 2021: $69.76 · 2022: $155 · 2023: $745 · 2024: $948 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.83 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $519.59 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.99 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $329.36 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $252.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.32 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $227.76 | 2019-2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $175.10 | 2022-2024 | Tyvaso |
| Mylan Specialty L.P. | $138.89 | 2019-2024 | Yupelri |
| Intuitive Surgical, INC. | $134.45 | 2024 | |
| Verona Pharma, INC. | $116.61 | 2025 | Ohtuvayre |
| Baxter Healthcare | $101.02 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $87.16 | 2023-2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $43.74 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $39.88 | 2024-2025 | Glassia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.33 | 2023-2024 | Xarelto |
| Vifor Pharma, INC. | $34.50 | 2024-2025 | Zemaira, Veltassa |
| Circassia INC. | $30.78 | 2019 | |
| Insmed, INC. | $27.07 | 2025 | Brinsupri, Arikayce |
| Viatris Specialty LLC | $25.55 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $24.31 | 2019 | |
| Inspire Medical Systems, INC. | $19.00 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $17.74 | 2025 | |
| Electromed, INC. | $14.38 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.